Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune in the last year for NDAs with priority review status, the consulting firm Parexel concludes in a new report.
You may also be interested in...
Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer.
Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer
Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer